$ADMS News

Last published 4y ago

4y agoADMS SUPNSupernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsGlobeNewswireROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits square
4y agoADMS SUPNSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender OfferGlobeNewswireROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed
5y agoADMS BRPM HFC PSXPMoore Kuehn Encourages PSXP, BRPM, HFC, and ADMS Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
5y agoADMS CRK HNRG LOKB+1Thinking about buying stock in Adamas Pharmaceuticals, Trevi Therapeutics, Live Oak Acquisition, Comstock Resources, or Hallador Energy?PR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMS, TRVI, LOKB, CRK, and HNRG. T
5y agoADMS SUPNSupernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product PortfolioGlobeNewswireAcquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022 Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure Tot
5y agoADMSAdamas Announces New Employment Inducement GrantsBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted sto
5y agoADMSAdamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health AwardsBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UC
5y agoADMSCognoa Appoints Seasoned Financial Executive, Tony Rimac, as Chief Financial OfficerPR NewswirePALO ALTO, Calif., Sept. 30, 2021 /PRNewswire/ -- Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced that Tony Rimac has joined as Chief Fi
5y agoADMSAdamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) CongressBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Par
5y agoADMSAdamas Announces New Employment Inducement GrantsBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company's common stock. The restricted stoc
5y agoADMSAdamas to Present at Upcoming September Investor ConferencesBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual i
5y agoADMSAdamas Announces New Employment Inducement GrantBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company's common stock. The restricted stoc
5y agoADMSAdamas Reports Second Quarter 2021 Financial ResultsBusiness WireSecond quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developi
5y agoADMSAdamas Pharmaceuticals Inc (ADMS) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsADMS earnings call for the period ending June 30, 2021.
5y agoADMSAdamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021Business WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30
5y agoADMSAdamas Announces Issuance of New Patents for GOCOVRI and ADS-4101Business Wire-Drug-product and method-of-use patents strengthen and diversify GOCOVRI's long-term patent portfolio- -Issuance of ADS-4101 patent in Japan for partial onset seizures in patients with epilepsy strengthens partnering opportunity- Adamas Pharmaceut
5y agoADMSAdamas Announces New Employment Inducement GrantBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees restricted stock units to acquire 44,500 shares of the company's common stock. The restricted stock
5y agoADMSAdamas to Present at Upcoming William Blair Biotech Focus ConferenceBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will p
5y agoADMSAdamas to Present at Upcoming SVB Leerink CNS ForumBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present "What's Happening in Park
5y agoADMSAdamas Announces New Employment Inducement GrantBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company's common stock. The restricted stoc
5y agoADMSNew Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's DiseaseBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, "Effects
5y agoADMSAdamas to Present at Upcoming June ConferencesBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upco
5y agoADMS ASXC GWHP MNKD+2The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026PR NewswirePALM BEACH, Fla., May 12, 2021 /PRNewswire/ -- Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges durin
5y agoADMSAdamas Reports First Quarter 2021 Financial ResultsBusiness WireFirst quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing
5y agoADMSAdamas Pharmaceuticals, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 10, 2021 / Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time. To listen to the event live or
5y agoADMSAdamas Announces New Employment Inducement GrantBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees restricted stock units to acquire 58,500 shares of the company's common stock. The restricted stock
5y agoADMS AXSM BLRX GWHP+1Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027PR NewswirePALM BEACH, Fla., May 5, 2021 /PRNewswire/ -- Parkinson's disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing ("dopaminergic") neurons in a specific area of the brain called substantia nigra. Symptoms generally d
5y agoADMSAdamas to Present at Upcoming BofA ConferenceBusiness WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will p
5y agoADMSAdamas Launches "Picture More Time" Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson's Disease and Care PartnersBusiness Wire- Results of a survey co-sponsored by PMD Alliance and Adamas showed the need for education in the Parkinson's community about OFF time and dyskinesia - - Disease education program provides resources for Parkinson's patients experiencing motor compl
5y agoADMSAdamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021Business WireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m
5y agoADMS AVXL BIIB GWHP+1Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026PR NewswirePALM BEACH, Fla., April 20, 2021 /PRNewswire/ -- While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pa
5y agoADMSSurvey data detailing impact of OFF time and dyskinesia in people affected by Parkinson's disease presented at American Academy of Neurology (AAN) Annual MeetingBusiness WireParkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological di
5y agoADMSAdamas Announces Two Presentations for the American Academy of Neurology 73rd Annual MeetingBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI® (amantadine) extended- ...
5y agoADMSAdamas to Present at Upcoming Needham ConferenceBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12 – 15, 2021 ...
5y agoADMSAdamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s diseaseBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Par ...
5y agoADMSAdamas Announces New Employment Inducement GrantBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Pla ...
5y agoADMSAdamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, plus the exercise in full by the underwriters of thei ...
5y agoADMSAdamas Pharmaceuticals Announces Pricing of Follow-on Public OfferingBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offer ...
5y agoADMSAdamas Pharmaceuticals Announces Launch of Follow-on Public OfferingBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas i ...
5y agoADMSAdamas Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.
5y agoADMSAdamas to Present at Upcoming Healthcare ConferencesBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences:
5y agoADMSAdamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021Business WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
5y agoADMSAdamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF EpisodesBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended ...
5y agoADMSAdamas Announces Settlement of Patent Litigation with ZydusBusiness WireEMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation ...
5y agoADMSAdamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021GlobeNewswire-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and...
5y agoADMSAdamas to Present at Upcoming ICR ConferenceGlobeNewswireEMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
5y agoADMSAdamas Completes Acquisition of OSMOLEX ER®GlobeNewswireEMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
5y agoADMSAdamas to Present at Upcoming H.C. Wainwright ConferenceGlobeNewswireEMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
5y agoADMSAdamas Announces New Employment Inducement GrantGlobeNewswireEMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
5y agoADMSAdamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty PartnersGlobeNewswireEMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...